Stefani Spranger, PhD, post-doctoral fellow, Department of Pathology, The University of Chicago Medicine, discusses the significance of melanoma intrinsic β-catenin signaling on immune exclusion and resistance to immunotherapies.
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More